Biogen Pharmachem Industries (531752) Q4 08/09 earnings summary

Executive summary

• FY08/09 ended with a net loss of ₹43.33m versus ₹2.44m in FY07/08, as expenses exceeded income; no dividend was recommended.

• Trading activity expanded sharply, while management planned further commodity trading and diversification into power generation.

Financial highlights

• Total income was ₹1,569.58m versus ₹85.24m in FY07/08; sales were ₹1,569.09m, with ₹0.12m in other income and ₹0.49m from inventory increase.

• Total expenses rose to ₹1,612.91m from ₹87.68m; administrative and general expenses were ₹3.51m versus ₹1.30m.

• Loss before and after tax was ₹43.33m versus ₹2.44m; tax and fringe benefit tax provisions were nil.

Outlook and guidance

• Management expected improved turnover and profitability from larger-scale trading operations and diversification into the power sector.

• Planned activities included trading agro commodities, precious metals and other goods, exploring gold, silver and diamond imports and exports, and establishing a wind turbine power-generation plant.